JPY3,709.00
1.48%
Tokyo, May 02, 08:15 am CET
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

DAIICHI SANKYO Stock price

JPY3,702.00
+120.00 3.35% 1M
-1,167.00 23.97% 6M
-650.00 14.94% YTD
-1,800.00 32.72% 1Y
+406.00 12.32% 3Y
+1,243.00 50.55% 5Y
+3,003.67 430.12% 10Y
Tokyo, Closing price Fri, May 02 2025
+47.00 1.29%
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

Key metrics

Market capitalization JPY6.91t
Enterprise Value JPY6.37t
P/E (TTM) P/E ratio 23.74
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.38
P/S ratio (TTM) P/S ratio 3.66
P/B ratio (TTM) P/B ratio 4.26
Dividend yield 2.11%
Last dividend (FY26) JPY78.00
Revenue growth (TTM) Revenue growth 17.77%
Revenue (TTM) Revenue JPY1.89t
EBIT (operating result TTM) EBIT JPY303.29b
Free Cash Flow (TTM) Free Cash Flow JPY-62.42b
Cash position JPY639.84b
EPS (TTM) EPS JPY155.96
P/E forward 24.19
P/S forward 3.30
EV/Sales forward 3.04
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a DAIICHI SANKYO forecast:

16x Buy
100%

Analyst Opinions

16 Analysts have issued a DAIICHI SANKYO forecast:

Buy
100%

Financial data from DAIICHI SANKYO

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,886,256 1,886,256
18% 18%
100%
- Direct Costs 415,797 415,797
0% 0%
22%
1,470,459 1,470,459
24% 24%
78%
- Selling and Administrative Expenses 662,551 662,551
15% 15%
35%
- Research and Development Expense 435,965 435,965
19% 19%
23%
371,943 371,943
53% 53%
20%
- Depreciation and Amortization 68,649 68,649
15% 15%
4%
EBIT (Operating Income) EBIT 303,294 303,294
65% 65%
16%
Net Profit 295,756 295,756
47% 47%
16%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Hiroyuki Okuzawa
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today